Treatment of Systemic Sclerosis Associated Interstitial Lung Disease

Journal of Clinical Rheumatology and Immunology

Iris Yan Ki Tang¹  So Ho² 

[1] Department of Medicine and Geriatrics, Kwong Wah Hospital, Hong Kong;Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong;

关键词: systemic sclerosis;    scleroderma;    interstitial lung disease;    pulmonary fibrosis;    lung disease;   

DOI  :  10.1142/S2661341720300050

来源: DOAJ

【 摘 要 】

Systemic sclerosis (SSc) is a systemic connective tissue disorder characterized by progressive skin and visceral organ fibrosis, vasculopathy, and immune dysregulation. Interstitial lung disease (ILD) is a common manifestation and major contributor to morbidity and mortality. Immunosuppression is usually indicated for extensive or progressive SSc-ILD. Recently, antifibrotic and biological therapies have been shown to be efficacious in treating SSc-ILD in various studies. In this article, we will descriptively review the latest evidence on the treatment of SSc-ILD.

【 授权许可】

Unknown